Trials Sponsors Conditions Drugs Pricing

You may not qualify if:

Symptomatic central nervous system (CNS) metastases which are neurologically unstable or requiring increasing doses of steroids within the 28 days prior to study entry to control their CNS disease and require local CNS-directed therapy
Systemic anticancer treatment 14 days prior to the first dose of study drug on Visit 1
Subjects who have undergone any major surgery\* (as judged by the investigator, excluding placement of vascular access) ≤ 28 days of the first dose of study drug on Visit 1 or who have not recovered from side effects of such therapy
\*Major surgery defined as a surgical operation within or upon the contents of the abdominal, pelvic, cranial or thoracic cavities and a procedure which given the locality, condition of patient, level of difficulty or length of time to perform, constitutes a hazard to life or function of an organ or tissue. Major surgery usually requires general anesthesia, a period of hospitalization of varying length (often a week) and may be performed by a surgical subspecialist.
Limited-field radiotherapy ≤ 7 days or extended-field thoracic radiotherapy \< 28 days of study drug on Visit 1
Subjects with
A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval \> 480 milliseconds (ms) (CTCAE grade 1) using Frederica's QT correction formula.
A history of additional risk factors for TdP (e.g., heart failure, hypokalemia, family history of Long QT Syndrome).
The use of concomitant medications that prolong the QT/QTc interval.
Subjects with impaired cardiac function or clinically significant cardiac disease such as:
Left ventricular ejection fraction \< 50%.
Clinically significant and/or uncontrolled heart disease such as congestive heart failure requiring treatment (NYHA Grade ≥ 2), uncontrolled hypertension, or clinically significant arrhythmia.
History of acute myocardial infarction or unstable angina pectoris \< 6 months prior to study entry.
Subjects who had a prior history of another malignancy over the last 5 years
Subjects able to swallow and retain orally administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major restriction of the stomach or bowels
+8 more criteria

Study Stopped

Phase I, FIH, MTD for MPT0B640, Multi-centre, Open-label, Subject With Locally Advanced or Metastatic Solid Malignancies

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

MPT0B640

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

MPT0B640

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record